2024
Modifications on histone tails in Parkinson's disease.
Mao Q, Luo Z, Wang K, Chen B, Wang Z, Zhang Y, Wang X, Luo X. Modifications on histone tails in Parkinson's disease. SciBase Neurology 2024, 2 PMID: 39145143, PMCID: PMC11323098, DOI: 10.52768/neurology/1017.Peer-Reviewed Original ResearchHistone modificationsEpigenetic regulation of genesGene regulatory regionsGene expression regulationHistone tail modificationsRegulation of genesHistone marksChromatin structureRepressive marksRegulatory regionsExpression regulationHistone tailsTail modificationsHistone H2AEpigenetic modificationsEpigenetic regulationEpigenetic mechanismsHistoneGene expressionGenesGSK-J4Neural stem cellsA-synucleinEnvironmental factorsParkinson's disease
2023
Pleiotropic Association of CACNA1C Variants With Neuropsychiatric Disorders
Wang Z, Lin X, Luo X, Xiao J, Zhang Y, Xu J, Wang S, Zhao F, Wang H, Zheng H, Zhang W, Lin C, Tan Z, Cao L, Wang Z, Tan Y, Chen W, Cao Y, Guo X, Pittenger C, Luo X. Pleiotropic Association of CACNA1C Variants With Neuropsychiatric Disorders. Schizophrenia Bulletin 2023, 49: 1174-1184. PMID: 37306960, PMCID: PMC10483336, DOI: 10.1093/schbul/sbad073.Peer-Reviewed Original ResearchConceptsGray matter volumeBipolar disorderNeuropsychiatric disordersIntracranial volumeSingle nucleotide polymorphismsParkinson's diseaseCACNA1C variantsCACNA1C mRNARisk allelesAlcohol use disorderAverage cortical thicknessTotal intracranial volumeMultiple psychiatric disordersFalse discovery rate correctionDifferent neuropsychiatric disordersCortical surface areaBrain cohortCortical thicknessIndependent cohortPsychiatric disordersUse disordersMatter volumeSubcortical structuresSubstance dependenceDiseaseAn Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson’s Disease
Jing XZ, Yuan XZ, Luo X, Zhang SY, Wang XP. An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson’s Disease. Current Neuropharmacology 2023, 21: 1806-1826. PMID: 35193486, PMCID: PMC10514518, DOI: 10.2174/1570159x20666220222150811.Peer-Reviewed Original ResearchConceptsNon-motor symptomsDopamine replacement therapyPD patientsMotor fluctuationsParkinson's diseaseNondopaminergic treatmentsReplacement therapyCertain non-motor symptomsTraditional dopamine replacement therapyLower urinary tract symptomsUrinary tract symptomsOngoing clinical trialsPotential adverse eventsManagement of motorPositive clinical implicationsManagement of hallucinationsDopaminergic strategiesMotor complicationsNondopaminergic drugsPD psychosisOrthostatic hypotensionTract symptomsAdverse eventsClinical benefitClinical efficacy
2021
Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease
Taximaimaiti R, Luo X, Wang XP. Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease. Current Neuropharmacology 2021, 19: 2233-2249. PMID: 33998990, PMCID: PMC9185775, DOI: 10.2174/1570159x19666210517115706.Peer-Reviewed Original ResearchConceptsNon-pharmacological treatmentExcessive daytime sleepinessRestless legs syndromeRapid eye movementSleep disordersParkinson's diseaseSide effectsCommon non-motor symptomSleep behavior disorderNon-motor symptomsCommon sleep disorderDeep brain stimulationSleep hygiene educationRelative side effectsQuality of lifeCognitive behavior therapyLegs syndromePD patientsPharmacological treatmentComplementary therapiesDaytime sleepinessSleep qualityBrain stimulationBehavior disorderDisease
2020
KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease
Mao Q, Wang X, Chen B, Fan L, Wang S, Zhang Y, Lin X, Cao Y, Wu YC, Ji J, Xu J, Zheng J, Zhang H, Zheng C, Chen W, Cheng W, Luo X, Wang K, Zuo L, Kang L, Li CR, Luo X. KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease. Frontiers In Neuroscience 2020, 14: 651. PMID: 32655362, PMCID: PMC7324786, DOI: 10.3389/fnins.2020.00651.Peer-Reviewed Original ResearchPutamen gray matter volumesSubstantia nigra pars compactaGray matter volumeParkinson's diseaseMRNA expressionSingle nucleotide polymorphismsPD riskIndependent cohortMatter volumeDevelopment of PDPars compactaDopaminergic neuronsPutamenPutamen volumeSignificant associationPD associationsRisk allelesDiseaseSelective lossCohortGene variants